Advances in the diagnosis and early management of gestational trophoblastic disease. Issue 1 (16th December 2022)

• Record Type: Journal Article
• Authors: Joyce, Caroline M; Fitzgerald, Brendan; McCarthy, Tommie V; Coulter, John; O'Donoghue, Keelin
• Is Part Of: BMJ medicine. Volume 1:Issue 1(2022)
• Publication Date: 2022-12-16
• Subjects: Pregnancy complications -- Pathology -- Medical oncology -- Biochemistry -- Genetics; Medicine -- Periodicals; 610
• DOI: 10.1136/bmjmed-2022-000321
• Languages: English
• ISSNs: 2754-0413

Abstract

Abstract : Gestational trophoblastic disease describes a group of rare pregnancy related disorders that span a spectrum of premalignant and malignant conditions. Hydatidiform mole (also termed molar pregnancy) is the most common form of this disease. Hydatidiform mole describes an abnormal conceptus containing two copies of the paternal genome, which is classified as partial when the maternal genome is present or complete when the maternal genome is absent. Hydatidiform mole typically presents in the first trimester with irregular vaginal bleeding and can be suspected on ultrasound but confirmation requires histopathological evaluation of the products of conception. Most molar pregnancies resolve without treatment after uterine evacuation, but occasionally the disease persists and develops into gestational trophoblastic neoplasia. Close monitoring of women after molar pregnancy, with regular measurement of human chorionic gonadotrophin concentrations, allows for early detection of malignancy. Given the rarity of the disease, clinical management and treatment is best provided in specialist centres where very high cure rates are achievable. This review looks at advances in the diagnosis and early management of gestational trophoblastic disease and highlights updates to disease classification and clinical guidelines. Use of molecular genotyping for improved diagnostic accuracy and risk stratification is reviewed and future biomarkers for the earlier detection of malignancy are considered.